BioFluidica, a privately held biotechnology company, plans to commercialize its LiquidScan Automated Liquid Biopsy System.
Agency allows marketing of the QuantideX qPCR BCR-ABL IS kit, the first nucleic acid-based quantitation test for use during treatment of rare leukemia.Read More
After its ASH 2014 debut, the RainDance HemOnc Consortium, an international panel of clinical research experts, will focus on developing assays for liquid biopsy research of myeloid disorders.Read More
A new collaboration plans to provide genomic profiling and information for patients that have been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas, and myeloproliferative and myelodysplastic diseases.Read More
The test has been shown to offer sensitivity for the detection of residual cancer cells in marrow or blood.Read More